匹妥布替尼抑制伊布替尼耐药MYD88突变淋巴瘤细胞中的ERK1/2促生存信号
共价BTK抑制剂在MYD88突变华氏巨球蛋白血症中高活性,BTKCys481突变导致获得性耐药并再激活ERK1/2。本研究显示匹妥布替尼可阻断p-ERK1/2、ERK1/2驱动的炎性细胞因子,并克服表达突变BTKCys481的MYD88突变淋巴瘤细胞的旁分泌介导耐药。
要点
- BTKCys481突变与共价BTK抑制剂获得性耐药相关,并伴随ERK1/2再激活。
- 匹妥布替尼阻断表达突变BTKCys481的MYD88突变淋巴瘤细胞中p-ERK1/2。
- 匹妥布替尼克服旁分泌介导的耐药,为BTKCys481突变淋巴瘤提供机制见解。
核心结论
- 匹妥布替尼在表达突变BTKCys481的MYD88突变淋巴瘤细胞中阻断p-ERK1/2和ERK1/2驱动的炎性细胞因子,并克服旁分泌介导的耐药。
研究设计与样本
- 本研究为体外细胞研究,使用表达突变BTKCys481的MYD88突变淋巴瘤细胞。
主要发现
- 共价BTK抑制剂在MYD88突变华氏巨球蛋白血症中高活性,并抑制NF-κB和ERK1/2相关信号。
- BTKCys481突变与共价BTK抑制剂获得性耐药相关,伴随ERK1/2再激活,促进炎性细胞因子分泌和BTK野生型肿瘤细胞的旁分泌介导耐药。
- 匹妥布替尼是一种非共价BTK抑制剂,结合于非BTKCys481位点。
- 匹妥布替尼阻断表达突变BTKCys481的MYD88突变淋巴瘤细胞中的p-ERK1/2和ERK1/2驱动的炎性细胞因子,并克服旁分泌介导的耐药。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Covalent Bruton's tyrosine kinase-inhibitors (cBTK-i) are highly active in MYD88-mutated (MYD88Mut) Waldenstrom's macroglobulinaemia and suppress nuclear factor kappa-light-chain-enhancer of activated B cells and extracellular signal-regulated kinases-1/2 (ERK1/2)-related signalling. BTKCys481 mutations are associated with cBTK-i acquired resistance and are accompanied by reactivation of ERK1/2 that promotes inflammatory cytokine secretion and paracrine-mediated resistance of BTK wild-type (BTKWT) tumour cells. Pirtobrutinib is a non-covalent BTK-inhibitor that binds at non-BTKCys481 sites. We show that pirtobrutinib blocked p-ERK1/2, ERK1/2-driven inflammatory cytokines, and overcame paracrine-mediated resistance in MYD88Mut lymphoma cells expressing mutated BTKCys481. Our results provide important mechanistic insights for the activity of pirtobrutinib in MYD88Mut lymphomas carrying BTKCys481 mutations.
引用
- Munshi M, Liu X, Kofides A, et al. ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells. Br J Haematol. 2024. PMID: 39295138. doi:10.1111/bjh.19756
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。